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Abstract
Background: Preterm birth is the most common cause of death and harm to newborn babies. Babies that are born
early may have difficulties at birth and experience health problems during early childhood. Despite extensive study,
there is still uncertainty about the effectiveness of progestogen (medications that are similar to the natural hormone
progesterone) in preventing or delaying preterm birth, and in improving birth outcomes. The Evaluating Progestogen
for Prevention of Preterm birth International Collaborative (EPPPIC) project aims to reduce uncertainty about the
specific conditions in which progestogen may (or may not) be effective in preventing or delaying preterm birth and
improving birth outcomes.
Methods: The design of the study involves international collaborative individual participant data meta-analysis
comprising systematic review, re-analysis, and synthesis of trial datasets.
Inclusion criteria are as follows: randomized controlled trials comparing progestogen versus placebo or non-
intervention, or comparing different types of progestogen, in asymptomatic women at risk of preterm birth. Main
outcomes are as follows; fetal/infant death, preterm birth or fetal death (<=37 weeks, <=34 weeks, <= 28 weeks),
serious neonatal complications or fetal/infant death, neurosensory disability (measured at 18 months or later) or
infant/child death, important maternal morbidity, or maternal death. In statistical methods, IPD will be synthesized
across trials using meta-analysis. Both ‘two-stage’ models (where effect estimates are calculated for each trial and
subsequently pooled in a meta-analysis) and ‘one-stage’ models (where all IPD from all trials are analyzed in one step,
while accounting for the clustering of participants within trials) will be used. If sufficient suitable data are available, a
network meta-analysis will compare all types of progesterone and routes of administration extending the one-stage
models to include multiple treatment arms.
Discussion: EPPPIC is an international collaborative project being conducted by the forming EPPPIC group, which
includes trial investigators, an international secretariat, and the research project team. Results, which are intended
to contribute to improvements in maternal and child health, are expected to be publicly available in mid 2018.
Systematic review registration: PROSPERO CRD42017068299
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Plain language summary
Preterm birth is the most common cause of death and
harm to newborn babies. In the USA, about one in every
10 babies is born preterm, before the 37th week of preg-
nancy. Preterm birth is more common in African Ameri-
can women, affecting about one in every seven babies. In
Europe, about 1 in 20 births is preterm, and in African
countries, almost 1 in 5 babies are delivered before
37 weeks.
Babies born early may have difficulties at birth and
health problems during early childhood. They are more
likely to die during their first year and to experience
long-term disabilities such as cerebral palsy, epilepsy,
blindness, and hearing loss. Reducing the numbers of
preterm births is therefore important to pregnant
women and their families, and is a global health priority.
Progestogens are medications that are similar to the
pregnancy hormone progesterone. They are thought to
help prevent preterm birth in women who may be at
higher risk of an early birth. Women who have had a
preterm birth in a previous pregnancy, have short cer-
vical length, or are carrying twins or triplets are at
greater risk of having a preterm birth. There are differ-
ent types of progestogen. Some are given as weekly
injections (shots). Others are given as daily vaginal gels
or tablets during the second and third trimesters of
pregnancy.
In total, around 45 clinical trials have studied the use
of progestogen in these types of pregnancies. Many of
these studies have been small and results have been
mixed. Several reviews of these trials have also been
completed. Some reviews have suggested that progesto-
gen reduces the rate of preterm birth, while others have
found no evidence of benefit. Further trials have been
completed since these reviews were published.
The Evaluating Progestogens for Prevention of Pre-
term birth International Collaborative (EPPPIC) has
been set up to reduce uncertainty about the specific
conditions in which progestogen may (or may not) be
effective in preventing or delaying preterm birth and
improving birth outcomes. It will help us learn to
whom it should be offered and in what form. EPPPIC
aims to identify all relevant clinical trials and to col-
lect and analyze the data collected on every woman
participating in these trials. It will combine similar
data across multiple studies. This is known as an
individual participant data (IPD) meta-analysis. Having
access to the ‘raw’ data collected in the trials will
allow the research team to carry out very detailed
analysis and better understand how and when proges-
togen may help.
The data will be used to compare use of progestogens
to standard obstetric care (with no progestogens) and to
compare different types of progestogen. The effect of
progestogens on preventing preterm birth, infant death,
complications at birth, and long-term disability will be
investigated. Of particular interest will be the effect of
progestogens in women with a twin (or triplet) preg-
nancy, in women who have had a preterm birth in a pre-
vious pregnancy, and in women with a short cervix
(which increases the risk of preterm birth).
This work is being carried out by a research team
based at the University of York, in partnership with
individual trial investigators and with a secretariat
comprising funders, and key trial and stakeholder rep-
resentatives. Findings will be published by the EPPPIC
group.
Introduction
Background
Preterm birth (defined as birth before 37 weeks of gesta-
tion) is the most common cause of neonatal morbidity
and mortality globally, with rates ranging from 5% in
European countries to 18% in African countries [1]. In the
USA, 9.84% of all babies and 13.75% of those born to non-
Hispanic black mothers were delivered preterm in 2016
(https://www.cdc.gov/nchs/data/vsrr/report002.pdf).
Infants born prematurely, particularly those born be-
fore 34 weeks, are at greater risk of having difficulties at
birth and health problems during infancy including
greater risks of dying during their first year [2]. They are
also more likely to experience long-term morbidity such
as cerebral palsy, epilepsy, blindness or hearing loss. Pre-
term birth can therefore have lifelong impact for individ-
uals and families. It can also have important economic
consequences, for families as well as for payers and pur-
chasers of health care. In 2005, the Institute of Medicine
estimated the annual societal cost of preterm birth in
the USA to be $26 billion [3]. Reducing rates of preterm
birth would therefore accrue significant health and fiscal
benefits.
Endogenous progesterone is important in maintaining
pregnancy, and decline of progesterone activity is be-
lieved to play a role in the onset of labor. Progestogens
(compounds with progesterone-like action) have been
regarded as promising therapeutic agents since the
1960s. Natural progestogens are similar to those pro-
duced by living organisms, while synthetic progestogens
including 17-hydroxyprogesterone caproate (17-OHPC)
are manufactured in the laboratory and have a different
chemical structure [4].
The cost of licensed proprietary 17-OHPC in 2011/
2012 has been reported as $690 per injection or
around $15,000 per pregnancy [5, 6], the cost of com-
pounded 17-OHPC as $285 per pregnancy, and vagi-
nal gels and suppositories as between $338 and $2499
per pregnancy [5].
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Current evidence and knowledge
The role of progestogen (mainly vaginal administration
of progesterone and intramuscular injection of 17-
OHPC) in preventing preterm birth has been extensively
studied in over 40 randomized controlled trials (RCTs)
and in several systematic reviews.
A Cochrane review of 36 RCTs, including 8523 women
and 12,515 infants [7] found that progestogens adminis-
tered by intramuscular injection or vaginal application
prolonged pregnancy and reduced neonatal mortality
and short-term morbidity. It noted that there was little
information on longer-term outcomes.
An IPD-MA that focused on vaginal administration of
progesterone in women with short cervix in mid-
trimester (< 25 mm), and included data from 5 RCTs,
775 women and 827 infants [8] provided strong evidence
in favor of intervention. However, a 2015 IPD-MA
examining effects in twin pregnancies that included 13
trials, 3768 women and 7536 babies found that 17-
OHPC did not reduce the incidence of a composite out-
come of adverse perinatal outcomes that included pre-
term birth; though a subgroup analysis suggested some
benefit in women with reduced cervical length [9]. An
IPD-MA of 3 RCTs of 232 triplet pregnancies found no
significant impact of 17-OHPC on outcome or duration
of pregnancy [10].
A large placebo controlled randomized trial of vagi-
nally administered progesterone that included 1228
women and focused on family-centered outcomes pub-
lished in 2016 found no significant effect on the primary
obstetric or neonatal outcomes, including longer-term
child health at 2 years of age [11]. When the relevant
subset of women enrolled in this trial were included in a
meta-analysis of women with singleton pregnancies and
a short cervix length [12], the combined evidence
showed significant benefit of vaginal progesterone in re-
ducing the risk of preterm birth and neonatal morbidity
and mortality. An updated meta-analysis of twin gesta-
tion pregnancies in 303 women with a short cervix en-
rolled from 6 RCTs [13] found a decrease in the risk of
preterm birth and some neonatal morbidities.
A recent systematic review included 680 women en-
rolled in 3 RCTs compared vaginal progesterone versus
17-OHPC in singleton pregnancies. However, as this
used aggregate data extracted from trial publications, it
was limited in scope, but reported similar effectiveness
for vaginal progesterone and 17-OHPC injection [14].
Rationale for a new systematic review with IPD meta-
analysis
Despite extensive study, there still remains uncertainty
regarding the specific conditions in which progestogen
may (or may not) be effective in preventing or delaying
preterm birth and in improving birth outcomes. Optimal
dose, route, and formulation of progestogens have not
been established. Resolving this uncertainty could have
important impact and provide more robust evidence to
help pregnant women at risk of preterm birth make
informed choices. Given the lifelong consequences, even
a small change in preterm birth rate could yield signifi-
cant benefit.
A comprehensive and up-to-date IPD-MA of all ran-
domized trials comparing progestogens with placebo or
routine care is a potentially powerful approach to resolv-
ing current uncertainty about the effectiveness of pro-
gesterone in preventing preterm birth.
Although several completed systematic reviews exist,
each has looked at different subsets of the at-risk popu-
lation and several new trials have since been completed.
The EPPPIC IPD-MA aims to bring together the total-
ity of existing evidence from randomized trials. It will
enable detailed analyses that can more appropriately ac-
count for heterogeneity within and between trials than
analyses based on aggregate data, and will apply the
same methods across different at risk populations. An
IPD network meta-analysis that also includes trials that
have compared vaginally administered progesterone,
17-OHPC, and oral progesterone will provide import-
ant additional evidence on comparative effectiveness
and safety.
The IPD approach will support analyses to explore
whether there are particular types of women or preg-
nancy who gain a greater degree of benefit from proges-
togens, or, conversely, women who gain little or no
benefit and who may therefore prefer to avoid the poten-
tial side effects of intervention.
Collaborative approach
EPPPIC will be an international partnership involving
trial investigators who have carried out eligible random-
ized trials, members of the secretariat and the IPD-MA
research team, who will work together to provide a de-
finitive evaluation of the existing evidence. The EPPPIC
IPD-MA research team, who have developed this proto-
col, have previously completed and published a number
of such collaborative IPD meta-analyses, which are illus-
trative of the collaborative model [e.g., [15, 16]]. The
EPPPIC secretariat includes two consumer representa-
tives who will provide perspective and feedback through-
out the project. We will also consult more widely with
relevant professional stakeholders, charities, and support
organizations in relation to the appropriateness of out-
comes and dissemination activity.
Aims and objectives
The aims of this study are to undertake a robust
evaluation of the benefits and harms of progestogens in
preventing preterm birth and associated morbidity and
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to determine to whom progestogen should be offered,
and in what form. This will contribute to improved
health and well-being of pregnant women and to im-
proved child health.
This systematic review and IPD-MA will assess the bene-
fits and harms of progestogen (in different forms, doses,
routes of administration, and timing) administered for the
prevention of preterm birth. It will investigate whether any
particular therapeutic approaches are more effective than
others, including evaluation of the comparative effective-
ness of vaginal progesterone and 17-OHPC. It will evaluate:
(1)Effectiveness of progestogen versus no active
intervention
(additional early co-treatment, e.g., cerclage, pessary;
and/or late treatment, e.g. tocolytics, is allowed provided
that permitted use does not differ between trial arms)
Separate analyses will be carried out for each type of
progestogen. Further exploratory analyses may
combine types of progestogen if there is no evidence
of differences in effectiveness between them.
(2)Effectiveness of vaginally administered progesterone
versus 17-OHPC versus oral progesterone
(additional early co-treatment, e.g., cerclage, pessary;
and/or late treatment, e.g. tocolytics, is allowed provided
that permitted use does not differ between trial arms)
It will also explore whether there are particular types
of women or pregnancy who derive greater benefit (or
harm) from intervention. Key clinical scenarios that
reflect patient populations defined by risk factor will be
explored and emphasized. Emphasis will be placed on
(but analyses not limited to) the following:
 Twin pregnancy with previous preterm birth and
maternal short cervix
 Twin pregnancy with previous spontaneous preterm
birth (any cervical length)
 Twin pregnancy with maternal short cervix, but no
previous preterm birth
 Twin pregnancy with no other risk factors
 Triplet pregnancy (likely to be too few trial
participants to split further)
 Singleton gestation with previous preterm birth and
maternal short cervix
 Singleton gestation with previous spontaneous
preterm birth (any cervical length)
 Singleton gestation with maternal short cervix, but
no previous preterm birth
Methods/design
Protocol development and registration
This protocol has been registered in PROSPERO
(CRD42017068299) and is reported in accordance with
the Preferred Reporting Items for Systematic review and
Meta-analysis Protocols (PRISMA-P) 2015 statement
[17]. Representatives of all trials identified during project
development (Table 1) have been invited to comment on
and contribute to the development of this protocol. For
transparency and to safeguard against perception of
academic bias, a record is kept of trial investigator
comment and the IPD-MA research team is responsible
for making methodological decisions. Feedback on
project design has also been obtained from consumer
representatives.
Inclusion and exclusion criteria
We aim to include all relevant trials irrespective of
whether they are published or unpublished, where tri-
als have been carried out, or which language they
have been managed and reported in. We aim to in-
clude any trial that completed recruitment before July
2016 (allowing 1 year between completion and EPP-
PIC’s data collection for trial investigators to
complete their own analyses). Such trials will be in-
cluded in any future updates.
Population
Trials including asymptomatic women at increased risk
of preterm birth including women who have experienced
previous spontaneous preterm birth, a multiple gestation
pregnancy, a short cervical length, or a positive fetal fi-
bronectin test at randomization. Trials of progestogen
given to women to prevent miscarriage will be excluded.
Trials of progestogen administered for immediately
threatened preterm birth including premature preterm
rupture of membrane or uterine contractions will be ex-
cluded. Singleton, twin, and triplet pregnancies will be
considered separately.
Intervention
Trials evaluating any form of progestogen are eligible,
including natural progesterone and synthetic 17 alpha-
hydroxyprogesterone caproate (17-OHPC), delivered by
any route including vaginal gels, capsules and suppositor-
ies, intramuscular injection, intravenous injection, and oral
administration. Different types of progestogen will be ana-
lysed separately. Planned and unplanned co-treatments are
permitted provided that co-treatments are equally permit-
ted on each intervention arm, or that trials with planned
co-interventions make un-confounded comparison (e.g.,
progestogen + cerclage versus cerclage alone). Trials where
administration of progestogen does not continue beyond
the 16th week of pregnancy will be excluded.
Comparators
Trials that compare progestogen with placebo or with
non-intervention will be included. Trials that compare
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progestogen with other active interventions such as
cerclage will be excluded. Trials that compare different
types of progestogen will be included in a secondary
network meta-analysis exploring particularly the com-
parative effectiveness of vaginal progesterone, 17-OHPC,
and oral dedroxyprogesterone acetate. A future project
may extend to an IPD evaluation of all active interven-
tions for prevention of preterm birth.
Outcomes
All trials that meet the above criteria will be included
and contribute to the IPD-MA prespecified outcomes
for which they collected data.
Study design
To limit potential for bias, only randomized controlled
trials will be included. Quasi-randomized studies will be
excluded. Cluster randomized and cross over trials will
also be excluded.
Trial identification
As is usual with IPD-meta-analyses, initial literature
searches and eligibility screening have been carried out
as part of protocol development. This is to ensure that a
draft protocol can be sent to trial investigators along
with their invitation to partner in the project, and is cen-
tral to the collaborative approach. Inclusion criteria were
established at the outset of the project.
Bibliographic searches of MEDLINE, Embase, CINAHL,
and the Maternity and Infant Care databases as well as the
Cochrane Pregnancy and Childbirth Review Group's spe-
cialized register were carried out during the development
phase of the project (this is usual for IPD meta-analyses)
and will be re-run at the end. An example MEDLINE
search strategy is provided in Appendix A. Trial registers
(ClinicalTrials.gov, ISCTRN, and the WHO ICTRP portal)
were also searched to identify any unpublished and/or im-
portant ongoing trials. Unpublished trials that completed
data collection before July 2016 were considered for inclu-
sion. This cut-off was designed to allow trial investigators
1 year after recruitment to complete their own research
and analyses. Authors of included trials have also been/
will be asked to identify any unpublished trials of which
they are aware.
Two researchers independently screened all titles
and abstracts retrieved from electronic database and
other searches. Full paper publications were then ob-
tained for potentially relevant trials. Where no full
paper existed and/or trial eligibility was uncertain,
study authors were contacted and asked to provide
further information.
Two researchers independently assessed the relevance
of each trial using the fullest available information. Any
discrepancies in screening decisions were resolved by
consensus and discussion with a senior team member or
clinician, as required.
‘Near miss’ studies that do not meet all of the inclu-
sion criteria and have therefore been excluded from
EPPPIC will be tabulated, and their bibliographic details
listed with reasons for exclusion in the final EPPPIC re-
port and PRISMA diagram.
Data provision and coding
Trial investigators will be invited to supply data in a stan-
dardized format using standardized coding developed for
EPPPIC. However, data will be accepted in any reasonable
format and re-coded as necessary by the research team.
Data will be requested for all women randomized, includ-
ing any who were excluded from original trial analyses.
Trial protocols and forms will also be collected. A list of
data items to be collected is given in Appendix B.
Data supplied will have all names and identifying num-
bers removed. Individuals will either be labeled with num-
bers known only to the original trial team or numbered
sequentially and trial investigators will be asked to keep a
record of these numbers. This will enable any data queries
to be traced back to the appropriate individual.
Data storage and confidentiality
All IPD will be received via secure online transfer, or
any other secure method such as secure FTP transfer or
encrypted email. All data will be anonymous and held in
a password-protected area of the Centre for Reviews and
Dissemination's (CRD) server. No attempt will be made
to re-identify participants and in the unlikely case of re-
identification, confidentiality will be maintained. Access
will be limited to staff working directly on the project.
Copying data to laptop computers or memory sticks will
be prohibited.
Critical appraisal, data checking, and quality assurance
Critical appraisal and assessment of data quality will be
based on trial protocols and publications and on IPD
checking. Risk of bias will be assessed using the
Cochrane risk-of-bias tool (RoB) [18]. Assessment will
be undertaken by one researcher and if discrepant from
RoB assessments reported in previous Cochrane [7] or
other systematic reviews, will be checked independently
by a second. Two researchers will independently assess
trials not previously assessed and reported in a Cochrane
or other good quality systematic review. Any disagree-
ments will be discussed with a senior member of the
EPPPIC IPD-MA research team.
All IPD will be checked on receipt. Data will be
checked for internal consistency, baseline imbalance,
and integrity of randomization. Patterns of missing data
will be examined. Baseline data will be tabulated and
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compared with the trial publication and any inconsisten-
cies noted. One researcher will run data checks, which
will be independently checked by a second researcher.
Findings of all data checking will be discussed with se-
nior members of the research team.
Each individual trial will be analyzed (main outcomes
only) and compared with corresponding published ana-
lyses (bearing in mind that there may be reasonable
discrepancies, if, for example, previously excluded partici-
pants have been reinstated in the analyses, or additional
follow up data have been provided). Any problems, uncer-
tainties, or queries will be passed back to the responsible
trial investigator for explanation and discussion.
Results of data checking may up- or down-weight impli-
cations of RoB assessments, for example, data checks may
show that there is no evidence that risk of bias arising
from the method of randomization has been realized. Any
datasets that are judged to be of insufficient quality or
completeness will be excluded from the analyses. This
may be for the trial as a whole or for particular outcomes
or analyses, depending on the nature of the problem.
Data description
Descriptive tables and a narrative summary outlining the
key design features and demographic characteristics of
each included trial will be produced. Excluded trials will
be listed with reasons for exclusion.
Planned analyses
A detailed statistical analysis plan will be developed
when the extent of available data is known, but before
starting meta-analysis.
Analyses will evaluate overall effectiveness of main and
additional outcomes on an intention to treat basis, that is,
participants will be analyzed according to allocated treat-
ment, irrespective of whether the treatment was received.
Three parallel but separate analyses focusing on (i)
singleton and (ii) twin and (iii) triplet pregnancies will
be undertaken. If there is no evidence of differences in
effectiveness of progestogen in these three types of preg-
nancy, further exploratory analyses will incorporate all
pregnancy types in a multi-level model. Twin and triplet
pregnancies may be combined if there are insufficient trip-
let data for a viable analysis, and there is no clear evidence
of differences between twin and triplet pregnancies. Separ-
ate analyses will be carried out for each type of progesto-
gen. Further exploratory analyses may combine types of
progestogen if there is no evidence of differences in effect-
iveness between them.
Maternal, pregnancy, neonatal, and longer-term devel-
opmental outcomes will be considered. A separate but
complementary focus group study on views of women
who have experienced preterm birth will identify out-
comes that are especially important to pregnant women
and their families, and which therefore lend themselves
to shared decision-making.
Outcomes align broadly with the Core Outcomes in
Women’s and Newborn health (CROWN) list [19].
Consideration of additional outcomes reflects the oppor-
tunity that IPD-MA provides to leverage maximum in-
formation from preexisting data. As many outcomes are
being explored, findings will be interpreted with the
knowledge that there is a high likelihood that statistically
significant results will arise by chance. Findings will
therefore be interpreted cautiously and in the round,
with biological plausibility and consistency across related
outcomes and across trials lending credence; and incon-
sistency suggesting that results may be spurious and
should be interpreted conservatively.
A final list of outcomes to be addressed will depend on
what variables trials have collected and are available from
the included trials. Outcomes with low numbers of events
may be combined into more general categories for formal
analysis. Appendix B lists the data items that will be
requested, including baseline and outcome variables.
Main outcomes
 Preterm birth or fetal death (< =37, <= 34, <= 28
weeks)
 Serious neonatal complications or fetal/infant
death
(broncho-pulmonary dysplasia, severe
intraventricular hemorrhage, nectrotizing
enterocolitis, confirmed sepsis, patent ductus
arteriosus, retinopathy of prematurity)
 Neurosensory disability (measured at 18 months
or later) or infant/child death
(cerebral palsy, visual impairment, hearing
impairment, epilepsy, intellectual impairment,
developmental delay)
 Important maternal morbidity or maternal death
(gestational diabetes, gestational hypertension,
preeclampsia, maternal infection)
 Fetal/infant death
(fetal death occurring at any point after trial entry,
stillbirth, or death of live born infant before hospital
discharge following birth, or to 28 days, whichever is
longer)
With component outcomes defined as follows
Additional outcomes
 Gestational age at birth
 Prolongation of pregnancy (interval between
randomization and delivery)
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 Prelabor spontaneous rupture of membranes (≤28,
≤34, ≤37 weeks and >37 weeks)
 Non-spontaneous onset of labor (medically induced
or caesarian before labor)
 Mode of birth (vaginal/caesarian birth)
 Gestational diabetes
 Preeclampsia
 Gestational hypertension
 Maternal infection
(chorioamnionitis during labor; intrapartum fever,
postpartum fever requiring antibiotics)
 Adverse/side effects of treatment
 Maternal death
 Fetal death/stillbirth (death of fetus after
randomization)
 Death of newborn (death of live born infant to
hospital discharge following birth)
 Birth weight (adjusted for gestational age and sex)
 Admission to neonatal intensive or special care unit
(NICU/SCU)
 Length of stay in NICU/SCU
 Respiratory distress syndrome (as defined in the trial)
 Use of respiratory support (mechanical, CPAP, high
flow nasal cannula)
 Bronchopulmonary dysplasia (as defined in trial)
 Periventricular leukomalacia
 Necrotizing enterocolitis (grade II or III)
 Neonatal infection (antenatal, early, late; as defined
in trial)
 Confirmed neonatal sepsis
 Patent ductus arteriosus (treated for)
 Severe intraventricular hemorrhage (grade III or IV)
 Retinopathy of prematurity (stage 3 or worse)
 Major congenital anomalies including cardiac
malformation
 Death and cause of death after discharge (from
hospital following birth)
 Cerebral palsy
 Visual impairment (visual acuity worse than 6/60,
20/200 in better eye)
 Hearing impairment (requiring amplification or worse)
 Epilepsy
 Intellectual impairment (as defined in trial)
 Developmental delay (mild, moderate, or severe on
Bailey scale or equivalent)
 Growth outcomes (including height, weight, head
circumference, if possible with reference to
appropriate growth chart centiles)
Neurosensory disabilities will be collected individually,
but it is anticipated that events will be few and that they
will need to be combined for analysis.
We will also analyze an exploratory composite out-
come of birth after 37 weeks of gestation of a surviving
baby with no serious neonatal complication or neurosen-
sory disability and with a surviving mother with no
long-term adverse events.
Analysis of potential effect modifiers
Potential effect modifiers will be investigated to explore
whether any particular therapeutic approaches are more
effective than others, and/or whether there are particular
types of women who derive greater benefit (or harm)
from intervention.
Trial-level intervention characteristics
 Intended dose (separately for each type of
progestogen)
 Intended early co-intervention(s)
Participant-level maternal and pregnancy characteris-
tics at trial entry
 Previous spontaneous preterm birth
 Gestational age at previous preterm birth
 Cervical length (continuous variable and using
thresholds ≤15 mm, ≤20 mm, ≤25 mm, ≤30)
 Positive fetal fibronectin test
(continuous variable and using thresholds ≥ 10 ng/
ml, ≥ 50 ng/ml, ≥ 200 ng/ml)
 Singleton or multiple gestation pregnancy
(singleton/multiple and singleton/twin/triplet
gestation pregnancy)
 Chorionicity and amnionicity
 Gestational age at randomization/initiation of treatment
 Maternal age
 Ethnicity (within comparable geographical locations)
 Assisted conception
 Chronic hypertension
 Prepregnancy diabetes
 Smoking during pregnancy
 Maternal body mass index (categorized using WHO
definitions)
Sensitivity and supplementary analyses
Sensitivity analyses will assess the impact of trial design
features and alternative approaches to synthesis. In
addition to those listed, further analyses may be under-
taken where principle analyses suggest that further investi-
gation may be informative. All analyses will be described
according to whether they were principle or sensitivity
analyses and whether they were preplanned or ad hoc.
 Supplemented (where possible) with aggregate data
from published reports of trials for which IPD is not
available
 Restricted to trials at low risk of bias with respect to
design features such as blinding
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 Restricted to trials that have been prospectively
registered
 Analysis of cervical length restricted to trials that
used ultrasound measurement
 Separate analyses of trials measuring developmental
outcomes directly and those that used questionnaires
 Separate analyses of trials measuring intellectual
impairment based on health records and those that
used parent reports
 Multivariable analysis including singleton and
multiple gestation pregnancies
 Analysis of ethnicity across all trial locations
 Analyses of covariate treatment interaction for
additional outcomes where analyses of main outcomes
suggests that further analysis may be informative
Statistical methods
Outcome measures
Dichotomous outcomes will be analyzed by calculating
the risk ratio for the effect of progestogen compared to
the control treatment (placebo or usual care). Odds ra-
tios may be used where risk ratios cannot be computed.
For continuous outcomes mean differences between
treatment arms will be reported. Hazard ratios will be
calculated for time-to-event outcomes.
Unit of analysis
Maternal and birth outcomes will use the pregnancy as
the unit of analysis. Infant outcomes will use the baby as
the unit of analysis. Because infants within a multiple
pregnancy are more similar to each other than to babies
in other pregnancies (statistically, they are not independ-
ent), analyses will be adjusted for this clustering (pro-
vided that the additional complexity does not make one-
stage models computationally intractable) [20].
One- and two-stage models
The IPD will be synthesized across trials using meta-
analysis. Both ‘two-stage’ models (where effect estimates
are calculated for each trial, and subsequently pooled in
a meta-analysis) and ‘one-stage’ models (where all IPD
from all trials are analyzed in one step, while accounting
for the clustering of participants within trials) will be
used.
Two-stage models
Two stage models will be used as an initial analysis for
all the main outcomes listed previously. Effect estimates
(relative risk (RR), mean difference (MD), or hazard ratio
(HR)) will be estimated for each trial, and then com-
bined using random effects meta-analysis. This will gen-
erate forest plots enabling results across trials to be
compared visually, heterogeneity investigated and differ-
ences across subgroups visualized. All of these
aspects will be essential in gaining a full understanding
of the underlying dataset, and will motivate the choice
of more complex one-stage models [21]. Heterogeneity
will be quantified using the I2 statistic.
One-stage models
One-stage models will be fitted for all outcomes. One-
stage analyses will pool IPD from all trials using a gener-
alized linear mixed model framework, which accounts
for potential heterogeneity across trials. For continuous
outcomes, linear mixed-effect models will be fitted. For
dichotomous outcomes, logistic mixed-effect models will
be used to calculate relative risks or odds ratios where
relative risks are computationally intractable.
Impact of trial and participant characteristics
The impact of the trial and patient-level characteristics
on treatment effect (that is, treatment–covariate interac-
tions) will be examined. For trial-level covariates, the
trials will be divided into groups according to the char-
acteristic and meta-analyses performed within each sub-
group. The more formal analysis of interactions will use
one-stage models, where treatment covariate interac-
tions will be added to existing one-stage models for
treatment effect. This will enable us to take account of
multiple participant characteristics when comparing pro-
gestogen with placebo or usual care (stratified by trial),
and will also enable exploration of potential treatment
interactions in a multivariable way. Models will be com-
pared in terms of goodness of fit and parsimony using
the Akaike information Criterion (AIC).
Time to event analyses
For the analyses of whether progestogen prolongs preg-
nancy, the hazard ratio for the effect of progesterone will
be calculated within each trial by fitting a Cox propor-
tional hazards model. Tests for proportional hazards
will be performed. Hazard ratios will be pooled across
trials using random effects meta-analysis. If the pro-
portional hazards assumption is reasonable, one-stage
random effects Cox models will be fitted. Treatment–
covariate interactions will be included in these models
as required.
Relative and absolute differences
Absolute differences will be calculated by applying the
resulting risk ratios or hazard ratios to appropriate base-
line incidences (calculated from suitable meta-analyses
across the trial control arms). Numbers needed to treat
and numbers needed to harm will similarly be calculated
for a range of plausible baseline measures.
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Unavailable trials and missing data
Every effort will be made to minimize the amount of
missing data, including requesting information for any
randomized participants that were excluded from the
original trial analyses. Where IPD cannot be obtained
for a trial, and where possible, aggregate data will be
extracted from publications and combined with the
IPD-MA results in a sensitivity analysis. Where
covariate data are missing for some participants, a
complete case analysis will be used in the first
instance (i.e., excluding patients with missing data). If
there are substantial missing data (around 10% for
any outcome or covariate), multiple imputation within
each trial will be used to impute missing covariates,
where this is computationally feasible. Trials that have
not recorded particular outcomes or particular
covariates will not contribute to those analyses.
Sensitivity analyses based on best and worst case
scenarios will be used to assess the impact of missing
outcome data.
Network meta-analysis
If sufficient suitable data are available, a network meta-
analysis will compare all types of progesterone and
routes of administration. This will incorporate direct evi-
dence from head to head trials and indirect evidence
from trials comparing each type of progestogen with no
intervention. Analyses will be conducted for the main
outcomes listed earlier.
Two statistical models will be used: first, the Bayesian
models of Lu and Ades [22], which are the most com-
monly used methods for network meta-analysis. The
one-stage meta-analysis models described above will also
be extended to include multiple treatment arms. The re-
sults of the two approaches will be compared. Both
approaches will use random effects to account for het-
erogeneity. Potential network inconsistency will be in-
vestigated by comparing results to results from direct
pairwise meta-analyses. If there is evidence of differ-
ences, node-splitting models will be used to investigate
inconsistency further.
Software
All analyses will be performed at CRD using the R soft-
ware package [23]. Two-stage analyses will additionally
use the meta and metafor libraries [24, 25]. One-stage
models will be fitted via the lme4 library, and one-stage
Cox models will use the coxme library. Forest plots will
be produced using in-house R code. For the network
meta-analysis, WinBugs and the GeMTC package in R
will be used. https://www.mrc-bsu.cam.ac.uk/software/
bugs/the-bugs-project-winbugs/
Reporting
Results will be presented and discussed at a dedicated
meeting of the EPPPIC group. Discussion will inform
the interpretation of results and development of the final
report. An audited list of comments received, and ac-
tions taken will be maintained. The results of the IPD-
MA will be reported in accordance with PRISMA-IPD
[26]. Authorship of the final journal publication will be
by the EPPPIC group. Plain language summaries of find-
ings will be produced.
Data repository
Our aspiration is that at the conclusion of our analyses,
data will be archived in a repository that will be devel-
oped and curated under the aegis of the Cochrane
Pregnancy and Childbirth Group. This would establish
the nucleus of a data repository that can grow over
time and underpin future IPD syntheses and other re-
search projects in pregnancy and childbirth topics.
Trial investigators will be given the opportunity to elect
to share their data supplied to EPPPIC with the reposi-
tory under a range of options that the repository will
offer. No further work would be required to share data
in this way. Participation in the repository is optional.
Trialists who participate in the EPPPIC group and IPD-
MA are not required to contribute their data to the
repository.
Discussion
The EPPPIC individual participant data meta-analysis is
an international collaborative project that will be carried
out on behalf of, and published by, the EPPPIC group.
All trial investigators who share data will be active par-
ticipating members of this group. The project is en-
dorsed and advised by the EPPPIC secretariat, which
includes trial investigators responsible for the largest tri-
als, representation from Cochrane, the US Patient-
Centered Outcomes Research Institute (PCORI), the Na-
tional Institute for Health Research (NIHR) in the UK,
the March of Dimes (US), and consumer stakeholders.
EPPPIC will pay attention to the views of consumer
representatives and of women at risk of preterm birth
(obtained in the separate but linked focus group project),
and will provide important data and tailored outputs to
inform shared decision-making and a stratified and more
personalized approach to intervention.
Initial results will be presented to all EPPPIC members
at a dedicated meeting planned for early 2018, with
associated discussion informing the development of a
final report and manuscript. The collaborative aspects
of the work and involvement of stakeholders and
those responsible for the included trials may help
reach consensus, and will be an important facet of
knowledge mobilization activity.
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Table 1 Provisional list of trials potentially eligible for inclusion in EPPPIC (progestogen versus placebo/usual care). This table will be
updated as new trials are identified. Publication details for individual trials are available on request
EPPPIC
identifier
Trial setting Recruitment
years
Progestogen type, dose,
intervention, period
Comparator
Main indication(s)
Gestation at randomization
Singleton/multiple
pregnancy
N
A: Eligible trials comparing progestogen with standard care or placeboa
1 Single center
Egypt (Cairo)
2008–2009 Vaginal
Micronized progesterone
400 mg suppository daily
18–24 to 37 weeks
Placebo
First pregnancy by IVF/ICSI
18–24 weeks
Singleton
Twin
313
2 Single center
Iran (Khorramabad)
– Vaginal
Progesterone
100 mg daily
24 to 34 weeks
Standard care
Previous SPTB
Prophylactic cerclage
Uterine anomalies
Gestation unclear
Singleton 150
3 Single center
Lebanon (Beirut)
2006–2012 Intramuscular injection
17-OHPC
250 mg weekly
16–20 to 36 weeks
Castor oil
Twin pregnancy
12–20 weeks
Twin 293
4 Multi center
USA
2004–2006 Intramuscular injection
17-OHPC
250 mg weekly
16–20 to 35 weeks
Castor oil
Triplet pregnancy
16–20 weeks
Triplet 134
5 Single center
Turkey (Istanbul)
2004–2007 Vaginal
Progesterone
100 mg suppository
daily 24 to 34 weeks
Placebo
Twin pregnancy
Previous SPTB
Uterine anomalies
24 weeks
Singleton
Twin
160
6 Multi center
USA
2004–2008 Intramuscular injection
17-OHPC
250 mg weekly
16–24 to 34 weeks
Castor oil
Trichorionic-triamniotic
triplet pregnancy
15–23 weeks
Triplet 81
7 Multi center
USA
2004–2009 Intramuscular injection
17-OHPC
250 mg weekly
16–24 to 34 weeks
Castor oil
Dichorionic-diamniotic
twin pregnancy
15–23 weeks
Twin 240
8 Multi center
Australia
2005–2009 Vaginal
Progesterone
100 mg suppository
nightly
20–24 to 34 weeks
Placebo
SPTB preceding pregnancy
18–24 weeks
Singleton 787
9 Single center
Brazil
(São Paulo)
1996–2001 Vaginal
Progesterone
100 mg suppository
nightly
24 to 34 weeks
Placebo
Previous SPTBPrevious
cerclage
Uterine anomalies
Gestation not reported
Singleton 157
10 Single center
Egypt
(Cairo)
– Vaginal
Progesterone
200 mg daily
24 to 34 weeks
Placebo
Twin pregnancy Twin 100
11 Multi center
International
2003–2006 Vaginal
Progesterone
200 mg suppository
nightly
24–25 to 34 weeks
Safflower oil
Short cervix (≤15 mm)
20–25 weeks
Singleton
twin
250
12 Single center
Pilot
USA
(Ohio)
2006–2009 Oral
Micronized progesterone
2 × 200 mg capsule daily
16–20 to 34 weeks
Placebo
Previous live SPTB
< 20 weeks
Singleton b33
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Table 1 Provisional list of trials potentially eligible for inclusion in EPPPIC (progestogen versus placebo/usual care). This table will be
updated as new trials are identified. Publication details for individual trials are available on request (Continued)
EPPPIC
identifier
Trial setting Recruitment
years
Progestogen type, dose,
intervention, period
Comparator
Main indication(s)
Gestation at randomization
Singleton/multiple
pregnancy
N
13 Multi center
USA
2007–2011 Intramuscular injection
17-OHPC
250 mg weekly
16–23 to 37 weeks
Castor oil
Nulliparous
Short cervix (< 30 mm)
16–23 weeks
Singleton 657
14 Single center
Finland
(Oulu)
– Intramuscular injection
17-OHPC
250 mg weekly
28–33 to 37 weeks
Placebo
Twin pregnancy
28–33 weeks
Twin 77
15 Multi center
International
2008–2010 Vaginal
Progesterone
90 mg gel daily
20–24 to 37 weeks
Placebo
Short cervix (10–20 mm)
19–24 weeks
Singleton 465
16 Single center
Egypt
(Cairo)
2006–2008 Intramuscular injection
17-OHPC
250 mg weekly
Second trimester to 36 weeks
Saline
Previous SPTB
Second trimester
Singleton 50
17 Single center
USA (Baltimore)
– Intramuscular injection
17-OHPC
250 mg weekly
Unclear to 37 weeks
Castor oil + benzyl benzoate
2 previous SPTB
2 SAs or (1 SPTB and 1 SA)
in immediately preceding
pregnancy
< 24 weeks
Singleton
Twin
50
18 Multi center
Netherlands
2006–2009 Intramuscular injection
17-OHPC
250 mg weekly
16–20 to 36 weeks
Castor oil
Multiple pregnancy
15–19 weeks
Twin
Triplet
Quadruplet
671
19 Single center
India (Chandigarh)
2004–2006 Vaginal
Micronized progesterone
100 mg capsule nightly
20–24 to 36 weeks
Standard care
Previous singleton SPTB
16–24 weeks
Singleton 100
20 Multi center
USA
1999–2002 Intramuscular injection
17-OHPC
250 mg weekly
16–20 to 36 weeks
Castor oil
Previous SPTB
15–21 weeks
Singleton 463
21 Single center
Albania (Tirana)
– Intramuscular injection
17-OHPC
Dose not reported, daily
15–22 to 34 weeks
Oral
Progesterone daily
(dose not reported, daily
15–22 to 34 weeks
Placebo
High risk of SPTB
15–22 weeks
– 121
22 Multi center
UK
2004–2008 Vaginal
Progesterone
90 mg gel daily
24 to 34 weeks
Placebo
Twin pregnancy
22 weeks
Twin 500
23 Multi center
UK
2009–2013 Vaginal
Progesterone
200 mg suppository
nightly
22–24 to 34 weeks
Placebo
Previous SPTB
Short cervix (≤ 25 mm)
Positive FFT and other risk
factors for SPTB
Singleton 1228
24 Multi center
USA
2004–2007 Vaginal
Progesterone
90 mg gel daily
18–23 to 37 weeks
Vaginal moisturizer
Singleton SPTB in most
recent pregnancy
16–23 weeks
Singleton 659
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Table 1 Provisional list of trials potentially eligible for inclusion in EPPPIC (progestogen versus placebo/usual care). This table will be
updated as new trials are identified. Publication details for individual trials are available on request (Continued)
EPPPIC
identifier
Trial setting Recruitment
years
Progestogen type, dose,
intervention, period
Comparator
Main indication(s)
Gestation at randomization
Singleton/multiple
pregnancy
N
25 Single center
Iran
(Tehran)
Intramuscular injection
17-OHPC
250 mg weekly
16–20 to 34 weeks
Placebo
Women ≥ 35 years – 260
26 Single center
India
(Delhi)
2005–2006 Oral
Micronized progesterone
100 mg capsule twice daily
18–24 to 36 weeks
Placebo
Previous SPTB
18–24 weeks
Singleton 150
27 Multi center
Denmark and Austria
2006–2008 Vaginal
Micronized progesterone
200 mg suppository daily
20–24 to 34 weeks
Safflower oil, gelatine, glycerol,
titanium dioxide (E171)
Diamniotic twin
pregnancy
Chorionicity
<16 weeks
18–24 weeks
Multiple 677
28 Multi center
USA
2004–2006 Intramuscular injection
17-OHPC
250 mg weekly
16–20 to 35 weeks
Castor oil
Twin pregnancy
16–20 weeks
Twin 661
29 Single center
Iran (Mashhad)
2007–2008 Intramuscular injection
17-OHPC
250 mg weekly
16 to 37 weeks
Standard care
Previous SPTB
Not reported
Singleton 100
30 Multi center
France
2006–2010 Intramuscular injection
17-OHPC
500 mg twice weekly
24–32 to 36 weeks
Standard care
Dichorionic diamniotic
twin pregnancy
Cervix ≤25 mm
24–32 weeks
Twin 165
31 Multi center
Spain
2006–2008 Vaginal
Progesterone
(1) 2 × 200 mg suppository
nightly
(2) 1 × 200 mg + 1 × placebo
suppository nightly
20 to 34 weeks
(3) 2 x placebo suppository
nighly Peanut oil + soy lecithin
Dichorionic diamniotic
twin pregnancy
20 weeks
Twin 294
32 Two center
Canada (Calgary)
2006–2010 Vaginal
Progesterone
90 mg gel daily
16–21 to 36 weeks
Placebo
Multiple gestation
16–21 weeks
Twin
Triplet
84
33 Single center
Brazil
(São Paulo)
2007–2013 Vaginal
Progesterone
200 mg suppository nightly
18–21 to 34 weeks
Placebo
Naturally conceived
diamniotic twin
pregnancy
18–21 weeks
Twin 390
34 Single center
Iran
(Tehran)
2010–2012 Vaginal
Progesterone
400 mg suppository nightly
16–22 to 36 weeks
Placebo
Previous SPTB
Cervix ≤ 28 mm + cerclage
Uterine anomalies
Uterine intramural
myoma ≥ 7 cm
16–22 weeks
Singleton 103
35 Two center
Egypt (Mansoura)
2012–2014 Vaginal
Progesterone
400 mg suppository daily
20–24 to 37 weeks
Standard care
Dichorionic twin pregnancy
Cervix 20–25 mm
20–24 weeks
Twin 250
36 Multi center
Netherlands
2009–2013 Vaginal
Micronized progesterone
200 mg suppository daily
22 to 34 weeks
Placebo
Nulliparous
Multiparous without SPTB
< 34 weeks gestation
Cervix ≤30 mm
18–22 weeks
Singleton 80
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Table 1 Provisional list of trials potentially eligible for inclusion in EPPPIC (progestogen versus placebo/usual care). This table will be
updated as new trials are identified. Publication details for individual trials are available on request (Continued)
EPPPIC
identifier
Trial setting Recruitment
years
Progestogen type, dose,
intervention, period
Comparator
Main indication(s)
Gestation at randomization
Singleton/multiple
pregnancy
N
37 Single center
India
(Shimla)
– Vaginal
Progesterone
100 mg suppository
24–28 to 34 weeks
Placebo
Previous SPTB
24–28 weeks
Singleton 80
38 Single center
Pakistan (Bahalwapur)
2011 Intramuscular injection
17P
250 mg weekly
16–20 to 36 weeks
Placebo
Previous SPTB
16–20 weeks
Singleton 60
45 Single center
USA (Jackson)
– Intramuscular injection
17-OHCP
250mg weekly
Up to 34 weeks or delivery
Castor oil
Twin pregnancy
20–30 weeks
Twin 30
B: Eligible trials comparing different types of progestogen
21 Single center
Albania (Tirana)
– Intramuscular injection
17-OHPC
Dose not reported, daily
15–22 to 34 weeks
Oral
Progesterone daily
(dose Dose
not reported, daily
15–22 to 34 weeks
Placebo
High risk of SPTB
15–22 weeks
– 121
39 Single center
Egypt (Tanta)
2010–2011 Vaginal
Micronized progesterone
200 mg suppository daily
20–24 to 34 weeks
Intramuscular injection
Progesterone
100 mg every 3rd day
20–24 to 34 weeks
Previous SPTB Cervix
≥ 15 mm
20–24 weeks
Singleton 160
40 Single center
Iran
(Yazd)
2012–2015 Vaginal
Progesterone
200 mg suppository daily
16–20 to delivery
Intramuscular injection
17-OHPC
250 mg weekly
16–20 weeks to delivery
Previous SPTB or
Cervix < 25 mm (not both)
16–20 weeks
Singleton 78
41 Single center
Saudi Arabia (Khamis Mushayt)
2009–2011 Vaginal
Micronized progesterone
90 mg gel daily
14–18 to 36 weeks
Intramuscular injection
17-OHPC
250 mg weekly
14–18 to 36 weeks
Previous mid-trimester SPTB
Previous cerclage
14–18 weeks
Singleton 518
42 Single center
Iran
(Tehran)
2012–2015 Vaginal
Progesterone
400 mg suppository daily
16–24 to 36 weeks
17-OHPC
250 mg weekly
16–24 to 36 weeks
Cervix < 25 mm
16–24 weeks
Singleton 304
43 Single center
USA (Oklahoma)
2007–2010 Intramuscular injection
17-OHPC
250 mg weekly
16–21 to 37 weeks
Vaginal
Micronized progesterone
100 mg suppository daily
16–21 to 37 weeks
Previous live singleton
SPTB
16–21 weeks
Singleton 174
Stewart et al. Systematic Reviews  (2017) 6:235 Page 13 of 17
Appendix A
Search strategy
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-
Process and Other Non-Indexed Citations, Ovid MEDLI-
NE(R) Daily and Ovid MEDLINE(R) (1946 to present).
Search strategy:
1 exp. Progesterone/ (68227)
2 progesterone$.mp. (103366)
3 hydroxyprogesterones/ or 17-alpha-
hydroxyprogesterone/ (4868)
4 17-hydroxyprogesterone caproate.mp. (63)
5 17-OHPC.mp. (48)
6 17OHPC.mp. (18)
7 17Pc.mp. (11)
8 progestins/ or 20-alpha-dihydroprogesterone/ or
algestone/ or algestone acetophenide/ or allylestrenol/
or desogestrel/ or dydrogesterone/ or flurogestone
acetate/ or gestrinone/ (12661)
9 20 alpha dihydroprogesterone.mp. (646)
10 20-alpha-dihydroprogesterone.mp. (646)
11 20 alpha-dihydroprogesterone.mp. (646)
12 20-alpha dihydroprogesterone.mp. (646)
13 algestone.mp. (171)
14 allylestrenol.mp. (154)
15 desogestrel.mp. (1802)
16 dydrogesterone.mp. (603)
17 flurogestone acetate.mp. (115)
18 gestrinone.mp. (264)
19 progestogen$.mp. (5291)
20 progestative$.mp. (248)
21 medroxyprogesterone acetate.mp. (7020)
22 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or
20 or 21 (123754)
23 Premature Birth/ (10507)
24 Obstetric Labor, Premature/ (13369)
25 premature birth$.mp. (13486)
26 preterm birth$.mp. (13895)
27 pre-term birth$.mp. (356)
28 pre term birth$.mp. (356)
29 PTB.mp. (4521)
30 preterm labor$.mp. (5634)
31 pre-term labor$.mp. (97)
32 pre term labor$.mp. (97)
33 preterm labor$.mp. (1729)
34 pre-term labor$.mp. (134)
35 pre term labor$.mp. (134)
36 PTL.mp. (947)
37 premature labor$.mp. (2314)
38 premature labor$.mp. (793)
39 preterm rupture$.mp. (422)
40 pre-term rupture$.mp. (8)
41 pre term rupture$.mp. (8)
42 premature rupture$.mp. (7345)
43 preterm deliver$.mp. (9824)
44 pre-term deliver$.mp. (406)
45 pre term deliver$.mp. (406)
46 premature deliver$.mp. (2897)
47 (perinatal adj3 (outcome$ or morbidit$ or
mortalit$)).ti,ab. (18841)
48 (neonatal adj3 (outcome$ or morbidit$ or
mortalit$)).ti,ab. (19966)
49 (pregnancy adj3 (outcome$ or morbidit$ or
mortalit$)).ti,ab. (26850)
50 (maternal adj3 (outcome$ or morbidit$ or
mortalit$)).ti,ab. (23799)
51 (developmental adj3 (outcome$ or morbidit$ or
mortalit$)).ti,ab. (3796)
52 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or
40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48
or 49 or 50 or 51 (114515)
53 22 and 52 (2300)
54 randomized controlled trial.pt. (469461)
55 controlled clinical trial.pt. (94440)
56 randomized.ab. (411777)
57 placebo.ab. (191551)
58 drug therapy.fs. (2019667)
59 randomly.ab. (285289)
60 trial.ab. (431708)
61 groups.ab. (1756447)
62 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 (4164393)
63 exp. animals/ not humans.sh. (4440485)
64 62 not 63 (3601842)
65 53 and 64 (820)
Table 1 Provisional list of trials potentially eligible for inclusion in EPPPIC (progestogen versus placebo/usual care). This table will be
updated as new trials are identified. Publication details for individual trials are available on request (Continued)
EPPPIC
identifier
Trial setting Recruitment
years
Progestogen type, dose,
intervention, period
Comparator
Main indication(s)
Gestation at randomization
Singleton/multiple
pregnancy
N
44 Single center
Iran (Yazd)
2010–2011 Intramuscular injection
17-OHPC
250 mg weekly
16 to 36 weeks
Placebo
Assisted conception
16 weeks
Singleton 106
aEligibility as of 15/07/2017, eligibility of all trials subject to final confirmation. Abbreviations used: IVF/ICSI in vitro fertilization/intracytoplasmic sperm injection,
N number randomized, SPTB spontaneous preterm birth, IMI intramuscular injection, SA spontaneous abortion, FFT fetal fibronectin test
bAnalyzed, not randomized (number randomized unclear)
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Appendix B
Data items to be collected
Trial level data items to be collected
 Trial registration number, if applicable
 Method of randomization
 Date trial started
 Date trial closed
 Control arm details
 For each treatment arm
 Type of progestogen (17-OHPC/
medroxyprogesterone acetate/natural)
 Route of administration (intramuscular/iv/vaginal/
oral)
 Dose (intended progestogen dose (mg) and number
of doses per week)
 Details of planned co-interventions/intervention
policy
 Method of measuring cervical length
 Method of calculating gestational age/due date
 Scale used to measure developmental delay
 Method of assessing intellectual impairment
 Staging and grading systems used
Individual-level data items to be collected
Baseline data at or close to randomization and maternal/
pregnancy outcomes
 Maternal unique ID (does not include participant
name or identifier)
 Date of randomization
 Gestational age at randomization
 Maternal age at randomization
 Ethnicity
 Assisted conception
 Parity
 Prior history of spontaneous preterm birth
 Gestational age at most recent previous preterm
birth
 Reason for most recent preterm birth
(preterm labor, preterm prelabor rupture of the
membranes, antepartum hemorrhage, preeclampsia,
other)
 Singleton/twin/triplet gestation pregnancy
 Prerandomization death in utero
 Chorionicity and amnionicity (multiple gestation
only)
 Cervical length
 Fetal fibronectin level
 Chronic (prepregnancy) diabetes
 Chronic hypertension
 Smoking during pregnancy
 Maternal BMI at randomization
 Treatment arm assigned
 Gestation at start and end of treatment
 Discontinuation of study treatment
 Co-treatment(s) received when asymptomatic
 Late use of antibiotics
 Late use of tocolytics
 Late use of corticosteroids
 Preeclampsia
 Prelabor spontaneous rupture of membranes and
gestational age at occurrence
 Labor onset
 Gestational age at birth
 Gestational diabetes mellitus
 Gestational hypertension
 Gestational hypertension
 Chorioamnionitis
 Intrapartum fever
 Post-partum fever
 Maternal death and gestation at which maternal
death occurs
 Adverse effects (vaginal irritation, itching, discharge,
discomfort; nausea; vomiting; hot flushes;
depression; headache; joint or pubic pain; swelling;
rash, bruising, itching at injection site; unspecified/
other)
 Serious adverse events, SUSARs
 Whether woman excluded from trial analysis and
reason for exclusion
For each baby born
 Maternal unique ID
 Baby ID
 Mode of birth
 Live or still born
 Estimated gestational age at death of still born
 Sex
 Birth weight
 Length and head circumference
 Admission to NICU/SCU, length of stay
 Age at discharge from hospital
 Assisted ventilation and duration
 Treated for retinopathy of prematurity
 Respiratory distress syndrome
 Treated for bronchopulmonary dysplasia
 Infection and type (antenatal, early onset, late
onset)
 Treated for necrotizing enterocolitis
 Confirmed neonatal sepsis
 Intraventricular hemorrhage
 Treated for patent ductus arteriosus
 Teratogenic effects/major anomalies
 Death of live born before hospital discharge and age
at death
 Cause of death
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 Whether new born excluded from trial analysis and
reason for exclusion
Where long-term developmental outcomes have been
collected
 Baby ID
 Cerebral palsy, severity (mild, moderate, severe)
 Visual impairment (acuity worse that 6/60 in better
eye or as defined in trial)
 Hearing impairment requiring amplification or
worse
 Epilepsy
 Intellectual impairment (as defined in trial)
 Developmental delay (mild/moderate/severe, Bailey
scale or equivalent)
 Growth outcomes (height, weight, head
circumference) and age at measurement
 Death of child and age at death and cause of death
 Whether child excluded from trial analysis and
reason for exclusion
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